
Please try another search
(Reuters) -CVS Health Corp said on Monday that David Joyner would return to head the U.S. diversified healthcare company's pharmacy services and tapped former Cigna Corp (NYSE:CI) executive Amy Bricker as its chief product officer for consumer business.
Joyner will become the chief of the pharmacy services segment, which also includes the company's pharmacy benefits management business Caremark, effective Jan. 30. He will succeed Alan Lotvin, who plans to retire in April, CVS said.
Bricker will start in the newly created role in February after serving as president of Express Scripts (NASDAQ:ESRX), rival Cigna Corp's pharmacy benefits unit.
The appointments follow some setbacks CVS faced in recent months in its businesses. Its largest health insurance plan for Medicare recipients received a lower performance rating from the U.S. Centers for Medicare and Medicaid Services in October. The lower rating could affect payments from the government for 2024, the company said.
In the same month, Centene (NYSE:CNC) Corp replaced Caremark with Express Scripts to manage the insurer's annual pharmacy spend of around $40 billion.
The loss of the account, along with the ratings decline, will likely reduce 2024 revenue by $2 billion, CVS said in November.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.